Boston Scientific Co. (NYSE:BSX) Shares Sold by Fulton Bank N.A.

Fulton Bank N.A. trimmed its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 15.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,967 shares of the medical equipment provider's stock after selling 3,544 shares during the quarter. Fulton Bank N.A.'s holdings in Boston Scientific were worth $2,014,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in BSX. Investment Management Corp VA ADV purchased a new stake in shares of Boston Scientific during the 4th quarter worth $25,000. Colonial Trust Co SC lifted its stake in shares of Boston Scientific by 1,625.0% in the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 260 shares during the period. TFC Financial Management Inc. boosted its holdings in Boston Scientific by 308.8% during the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock worth $25,000 after buying an additional 210 shares in the last quarter. Sunbeam Capital Management LLC acquired a new position in Boston Scientific during the fourth quarter worth about $26,000. Finally, Ameriflex Group Inc. purchased a new position in Boston Scientific in the fourth quarter valued at about $31,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Arthur C. Butcher sold 17,314 shares of Boston Scientific stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the transaction, the executive vice president now owns 22,235 shares in the company, valued at approximately $2,269,304.10. The trade was a 43.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP John Bradley Sorenson sold 4,572 shares of the stock in a transaction on Monday, May 5th. The shares were sold at an average price of $104.54, for a total value of $477,956.88. Following the completion of the sale, the executive vice president now owns 18,705 shares of the company's stock, valued at approximately $1,955,420.70. This represents a 19.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 411,970 shares of company stock valued at $42,406,693 in the last ninety days. Company insiders own 0.50% of the company's stock.

Boston Scientific Trading Down 0.9%

Boston Scientific stock traded down $0.92 during trading on Friday, hitting $101.92. The company's stock had a trading volume of 6,358,679 shares, compared to its average volume of 6,455,483. The stock's fifty day moving average is $100.47 and its 200 day moving average is $98.29. Boston Scientific Co. has a 1-year low of $71.88 and a 1-year high of $107.17. The stock has a market capitalization of $150.78 billion, a price-to-earnings ratio of 81.55, a P/E/G ratio of 2.79 and a beta of 0.68. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The company had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. During the same quarter in the prior year, the company posted $0.56 EPS. The company's quarterly revenue was up 20.9% compared to the same quarter last year. As a group, equities research analysts predict that Boston Scientific Co. will post 2.85 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on BSX. Erste Group Bank raised Boston Scientific to a "strong-buy" rating in a research note on Thursday, May 8th. Argus set a $130.00 target price on Boston Scientific in a report on Tuesday, February 18th. Truist Financial raised their price target on Boston Scientific from $113.00 to $117.00 and gave the company a "buy" rating in a research report on Thursday, April 24th. Morgan Stanley boosted their price objective on shares of Boston Scientific from $120.00 to $125.00 and gave the stock an "overweight" rating in a research report on Friday, May 16th. Finally, Evercore ISI raised their target price on shares of Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Twenty-one investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Boston Scientific has a consensus rating of "Buy" and an average price target of $116.00.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.